Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the Hodgkin lymphoma study is displayed with its study details, including eligibility criteria, treatment plan, locations, outcomes, and a study protocol document.
    Difference
    62%
    Check dated 2026-11-11T01:37:14.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T23:46:58.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide NIH transition notice appears above the 403 error message, and the site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:48:34.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-07T00:46:35.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page in place of the study details, signaling an access restriction or server issue preventing the study record from loading.
    Difference
    20%
    Check dated 2026-09-23T00:57:23.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates a small editorial update to the page content and formatting.
    Difference
    0.1%
    Check dated 2026-09-16T00:14:05.000Z thumbnail image

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.